Mucosis B.V.
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands
Trade Register / KvK: 02096219
We protects our inventions by filing patents in all major markets and by maintaining non-patentable know how as a trade secret. Our Mimopath™ technology is broadly protected by a number of granted patents. In addition, we also file patent applications for various inventions related our technology and vaccine candidates.
31.05.10 Mucosis receives financial support from the Dutch government for its FluGEM program
more >
27.04.10 Mucosis appoints Dr. Roberto Grimandi as chief medical officer
more >
22.09.09 Mucosis receives key US patent covering its Mimopath™ technology
more >
28.01.09 Mucosis B.V. and PATH start development of pneumococcal vaccines
more >
15.12.08 Mucosis B.V. and TNO announce flu vaccine research and development partnership.
more >
10.12.07 News article in “Het Financieele Dagblad”.
more >
06.11.08 Mucosis B.V. appoints Dr. Govert Schouten as CEO. more >
10.09.07 Mucosis raises € 3 million in first financing round more >